Compare Eli Lilly And Co (LLY) vs Nano Dimension Ltd - ADR (NNDM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Nano Dimension Ltd - ADR — how do they compare? Eli Lilly And Co trades at $1,177 (market cap $1.04T), while Nano Dimension Ltd - ADR trades at $1.55 (market cap $328.52M). The key difference: Eli Lilly And Co is far larger — about 3165.7× Nano Dimension Ltd - ADR's market cap, and Eli Lilly And Co pays a 0.59% dividend while Nano Dimension Ltd - ADR pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Nano Dimension Ltd - ADR for 43 Days on average.
| LLY | NNDM | |
|---|---|---|
Market Cap | $1.04T | $328.52M |
Volume | 3,064,878 | 1,160,945 |
Sector | Health | Technology |
52-Week High | $1.28K | $2.14 |
52-Week Low | $799.57 | $1.21 |
Typical Hold Time | 93 Days | 43 Days |
Enterprise Value | $1.09T | -$76.33M |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
Nano Dimension (NNDM) trades at $1.555, showing modest daily gains of 0.32%. The technical picture remains bearish with negative moving average signals, while fundamentals reveal significant challenges including a -135.18% net income margin and persistent cash burn. Recent developments include leadership changes and strategic divestitures aimed at reducing annual cash burn by $25 million, with the MarkForged sale expected to close in late 2026.
Despite trading below book value (P/B 0.68), NNDM faces substantial execution risks amid ongoing losses and negative cash flow. The company's restructuring efforts and asset sales provide potential catalysts, but investors should weigh the high-risk profile against the discounted valuation. Near-term performance hinges on successful cost reduction and revenue stabilization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Nano Dimension Ltd - ADR
Nano Dimension Ltd is engaged in research and development of a three-dimensional printer that prints electronic circuit boards, also known as printed circuit boards, and ink materials and products based on nanotechnology. Its products consist of two main product lines - Dragonfly 2020 3D printer and proprietary ink products. The company's Dragonfly 2020 3D printer currently in development uses proprietary ink and integrated software to quickly create fully functioning PCB prototypes. Geographically, it generates maximum revenue from the USA followed by the Asia Pacific and Europe and Israel. It serves the Commercial, Research and Printing services industries.
Read more on NNDM →
